Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies.
BACKGROUND
The suitability of (C57BL/6 TRAMP x C57BL/6)F1 transgenic (TRAMP+) mice with well- to moderately-differentiated prostate cancer (PCa) was assessed for pre-clinical therapeutic studies.


METHODS
TRAMP+ and TRAMP- mice were assessed for variability in genitourinary tract weight, seminal vesicle weight, prostate weight/volume and histopathology. Time-points included the reported ages of average tumour onset (approximately 25 weeks) and PCa-induced death (approximately 33 weeks).


RESULTS
Seventy % of TRAMP+ mice aged 25-33 weeks had well- to moderately-differentiated PCa. At 25-28 weeks, the mean genitourinary tract weight was 2X greater and the mean prostate weight/volume was 1.5X more in TRAMP+ than in TRAMP- mice, respectively. Prostate weight/volume showed significant increases (p < 0.0001) by 2X and 3X, respectively by 31-33 weeks of age.


CONCLUSIONS
The window for using the TRAMP model successfully for pre-clinical experimentation is 25-33 weeks provided that mice with poorly-differentiated PCa showing a large tumour burden are excluded.
Martiniello-Wilks
Rosetta
R
Oncology Research Centre, Prince of Wales Hospital Clinical School of Medicine, Faculty of Medicine, University of New South Wales, Level 2, Clinical Sciences Building, Barker Street, Randwick, NSW, 2031, Australia. r.martiniello@unsw.edu.au
Dane
Allison
A
Mortensen
Elin
E
Jeyakumar
Geetha
G
Wang
Xiao Yang
XY
Russell
Pamela J
PJ
D000818:Animals; D004195:Disease Models, Animal; D018450:Disease Progression; D005260:Female; D015316:Genetic Therapy / Q000379:methods; D008207:Lymphatic Metastasis; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D011355:Prodrugs / Q000493:pharmacokinetics / Q000494:pharmacology; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy; D012669:Seminal Vesicles / Q000473:pathology
D011355:Prodrugs